Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

ClinicalTrials.gov ID: NCT04532749

Public ClinicalTrials.gov record NCT04532749. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Study identification

NCT ID
NCT04532749
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Enrollment
212 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 74 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 14, 2020
Primary completion
May 23, 2022
Completion
Jul 13, 2022
Last update posted
Jun 3, 2025

2020 – 2022

United States locations

U.S. sites
26
U.S. states
12
U.S. cities
23
Facility City State ZIP Site status
Altea Research Institute Phoenix Arizona 85012
Preferred Research Partners Little Rock Arkansas 72211
Behavioral Research Specialists LLC Glendale California 91206
Sun Valley Research Center Imperial California 92251
Alliance for Research Long Beach California 90807
Excell Research Inc Oceanside California 92056
California Neuroscience Research Medical Group, Inc. Sherman Oaks California 91403
Pharmax Research Clinic Inc Miami Florida 33126
Innova Clinical Trials Miami Florida 33133
Harmony Clinical Research Inc North Miami Beach Florida 33162
Medical Research Group of Central Florida Orange City Florida 32763
Synexus Research Orlando Orlando Florida 32806
Stedman Clinical Trials Tampa Florida 33613
Compass Research LLC-Bioclinica Research The Villages Florida 32162
Synexus Clinical Research US Inc Atlanta Georgia 30328
Rush University Medical Center Chicago Illinois 60612
Uptown Research Institute, LLC Chicago Illinois 60640
Phoenix Medical Research, Inc. Prairie Village Kansas 66206
Michigan Clinical Research Institute Ann Arbor Michigan 48108
Eastside Comprehensive Medical Services New York New York 10128
Community Research Management Associates, Inc. Cincinnati Ohio 45212
Patient Priority Clinical Sites LLC Cincinnati Ohio 45215
Intend Research Norman Oklahoma 73069
IPS Research Company Oklahoma City Oklahoma 73106
InSite Clinical Research LLC DeSoto Texas 75115
Pillar Clinical Research, LLC Richardson Texas 75080

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04532749, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 3, 2025 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04532749 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →